• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    LifeVantage Appoints Dayton Judd to the Board of Directors

    2/15/24 4:05:00 PM ET
    $FTLF
    $LFVN
    $OPXS
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FTLF alert in real time by email

    SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Dayton Judd to the Company's Board of Directors (the "Board"), effective immediately, in an expansion of the Board. The Company has had discussions with Bradley L. Radoff and Sudbury Capital Fund, LP (collectively with certain of their affiliates, the "Radoff-Sudbury Group"), which owns approximately 12.6% of the Company's outstanding stock, since the Company's fiscal year 2024 annual meeting of shareholders held on November 6, 2023. During these discussions, the Company and the Radoff-Sudbury Group worked together to create a framework for long-term collaboration between the parties. The appointment of Dayton Judd to the Board is in connection with a Cooperation Agreement entered into between the Company and the Radoff-Sudbury Group.

    Steve Fife, LifeVantage's President and Chief Executive Officer, commented, "We welcome Dayton to the Board and believe his insights and perspective will benefit the Company and its shareholders. The LV360 initiatives are driving improving profitability and we remain on track to return Adjusted EBITDA margins back to double-digit levels. Coupled with our strong balance sheet, we expect to continue returning a meaningful portion of excess free cash flow to shareholders through dividends and share repurchases."  

    "I'm thrilled to join the Board and look forward to working closely with my fellow directors and the management team as we continue focusing on driving value for all shareholders," said Dayton Judd. "With its unique assortment of high-quality, innovative products and a powerful business model, LifeVantage is well positioned for growth, improved profitability and higher returns on capital."

    "Dayton is an accomplished executive with a strong track record in, and deep understanding of, the health and wellness industry," said Ray Greer, Chairman. "The combination of his financial and industry expertise is a great addition to the Board. We appreciate our engagement with the Radoff-Sudbury Group and are mutually aligned on the pathway to maximizing value for all shareholders."

    The Radoff-Sudbury Group has agreed to abide by certain customary standstill, voting commitment and other provisions in connection with the Cooperation Agreement. The full agreement between the Company and the Radoff-Sudbury Group will be filed on a Form 8-K with the U.S. Securities and Exchange Commission ("SEC").

    Dayton Judd Biography

    Dayton Judd has served as the Chief Executive Officer of FitLife Brands, Inc. (NASDAQ:FTLF) ("FitLife"), a national provider of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers, since February 2018, and founder and Managing Member of Sudbury Capital Management, LLC, a provider of investment advisory services, since 2012. Prior to that, he served as a Portfolio Manager for Q Investments, L.P., a multi-billion-dollar hedge fund, from 2007 through 2011, and held various positions at McKinsey & Company, Inc., a global management consulting firm, from 1996 to 1998 and again from 2000 to 2007. Mr. Judd currently serves as Chairman of FitLife, where he has served as a director since 2017, and has also served as a director of Optex Systems Holdings, Inc. (NASDAQ:OPXS), a manufacturer of optical sighting systems and assemblies, since October 2022, where he also serves as Audit Committee Chair. Mr. Judd is a Certified Public Accountant. He received an M.B.A. with high distinction from Harvard Business School, where he was a Baker Scholar, and earned his M.S. and B.S., summa cum laude, in Accounting from Brigham Young University.

    About LifeVantage Corporation

    LifeVantage Corporation (NASDAQ:LFVN), the activation company, is a pioneer in nutrigenomics, the study of how nutrition and naturally occurring compounds affect human genes to support good health. The Company engages in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath & body, and targeted relief products. The Company's line of scientifically-validated dietary supplements includes its flagship Protandim® family of products, LifeVantage® Omega+, ProBio, IC Bright®, Daily Wellness, Rise AM, Reset PM, and D3+ dietary supplements, the TrueScience® line of skin, hair, bath & body, and targeted relief products. The Company also markets and sells Petandim®, its companion pet supplement formulated to combat oxidative stress in dogs, Axio®, its nootropic energy drink mixes, and PhysIQ, its smart weight management system. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.

    Cautionary Note Regarding Forward Looking Statements

    This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," "may be," and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, the impact of COVID-19 on our business, expected financial performance, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments as a result of future COVID-19 developments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Reports on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the SEC. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.

    Investor Relations Contact:

    Reed Anderson, ICR

    (646) 277-1260

    [email protected]



    Primary Logo

    Get the next $FTLF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FTLF
    $LFVN
    $OPXS

    CompanyDatePrice TargetRatingAnalyst
    FitLife Brands Inc.
    $FTLF
    3/17/2025$21.00Buy
    Lake Street
    Lifevantage Corporation
    $LFVN
    1/14/2025$35.00Buy
    Craig Hallum
    Lifevantage Corporation
    $LFVN
    12/19/2024$26.00Buy
    Lake Street
    FitLife Brands Inc.
    $FTLF
    9/3/2024$40.00Buy
    ROTH MKM
    More analyst ratings

    $FTLF
    $LFVN
    $OPXS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FitLife Brands Announces First Quarter 2025 Results

      OMAHA, NE, May 15, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2025. Highlights for the first quarter ended March 31, 2025 include: Total revenue was $15.9 million, 4% lower than the first quarter of 2024.  Online sales were $10.6 million, representing 67% of total revenue and down 2% compared to the first quarter of 2024.Gross margin was 43.1% compared to 44.0% during the first quarter of 2024.Net income for the first quarter of 2025 was $2.0 million compared to $2.2 million during th

      5/15/25 7:30:00 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • LifeVantage Declares Quarterly Dividend

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company's Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corporation LifeVantage Corporation (NASDAQ:LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally o

      5/6/25 4:06:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

      SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximately 22.1%;Revenue in the Americas increased 29.5%, and revenue in Asia/Pacific & Europe decreased 7.2%. Excluding the negative impact of foreign currency fluctuations, third quarter

      5/6/25 4:05:00 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FTLF
    $LFVN
    $OPXS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Dayton Judd sold $170,370 worth of shares (18,377 units at $9.27) (SEC Form 4)

      4 - Optex Systems Holdings Inc (0001397016) (Issuer)

      6/17/25 6:23:19 PM ET
      $OPXS
      Electronic Components
      Technology
    • Director Lewis Darwin bought $4,873 worth of shares (379 units at $12.86), increasing direct ownership by 0.33% to 116,767 units (SEC Form 4)

      4 - Lifevantage Corp (0000849146) (Issuer)

      6/17/25 4:11:27 PM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Malhotra R. Rimmy sold $46,850 worth of shares (5,000 units at $9.37) (SEC Form 4)

      4 - Optex Systems Holdings Inc (0001397016) (Issuer)

      6/11/25 4:05:19 PM ET
      $OPXS
      Electronic Components
      Technology

    $FTLF
    $LFVN
    $OPXS
    SEC Filings

    See more
    • SEC Form 144 filed by Optex Systems Holdings Inc.

      144 - Optex Systems Holdings Inc (0001397016) (Subject)

      6/16/25 8:27:00 AM ET
      $OPXS
      Electronic Components
      Technology
    • Optex Systems Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Optex Systems Holdings Inc (0001397016) (Filer)

      5/22/25 5:29:42 PM ET
      $OPXS
      Electronic Components
      Technology
    • FitLife Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

      5/15/25 8:00:17 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care

    $FTLF
    $LFVN
    $OPXS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on FitLife Brands with a new price target

      Lake Street initiated coverage of FitLife Brands with a rating of Buy and set a new price target of $21.00

      3/17/25 8:22:47 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • Craig Hallum initiated coverage on Lifevantage with a new price target

      Craig Hallum initiated coverage of Lifevantage with a rating of Buy and set a new price target of $35.00

      1/14/25 8:36:52 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lake Street initiated coverage on Lifevantage with a new price target

      Lake Street initiated coverage of Lifevantage with a rating of Buy and set a new price target of $26.00

      12/19/24 8:39:43 AM ET
      $LFVN
      Biotechnology: Pharmaceutical Preparations
      Health Care